JPWO2019175218A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019175218A5 JPWO2019175218A5 JP2020546939A JP2020546939A JPWO2019175218A5 JP WO2019175218 A5 JPWO2019175218 A5 JP WO2019175218A5 JP 2020546939 A JP2020546939 A JP 2020546939A JP 2020546939 A JP2020546939 A JP 2020546939A JP WO2019175218 A5 JPWO2019175218 A5 JP WO2019175218A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- human
- seq
- tumor
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305271.1 | 2018-03-13 | ||
| EP18305271 | 2018-03-13 | ||
| PCT/EP2019/056250 WO2019175218A1 (en) | 2018-03-13 | 2019-03-13 | Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517130A JP2021517130A (ja) | 2021-07-15 |
| JP2021517130A5 JP2021517130A5 (https=) | 2023-10-04 |
| JPWO2019175218A5 true JPWO2019175218A5 (https=) | 2023-10-04 |
Family
ID=61972458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546939A Pending JP2021517130A (ja) | 2018-03-13 | 2019-03-13 | 抗ヒトＳＩＲＰａｖ１抗体の使用および抗ｖ１抗体を製造する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11884723B2 (https=) |
| EP (1) | EP3765512A1 (https=) |
| JP (1) | JP2021517130A (https=) |
| KR (1) | KR20210006338A (https=) |
| CN (1) | CN112105646A (https=) |
| AU (1) | AU2019233577A1 (https=) |
| BR (1) | BR112020017709A2 (https=) |
| CA (1) | CA3091468A1 (https=) |
| CL (1) | CL2020002305A1 (https=) |
| EA (1) | EA202091859A1 (https=) |
| MX (1) | MX2020009121A (https=) |
| PH (1) | PH12020551491A1 (https=) |
| WO (1) | WO2019175218A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66062B1 (sr) | 2016-04-14 | 2024-11-29 | Ose Immunotherapeutics | Nova anti-sirpa antitela i njihove terapijske primene |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| CN118027200A (zh) | 2016-12-09 | 2024-05-14 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| JP7395471B2 (ja) | 2017-10-13 | 2023-12-11 | オーセ イミュノセラピューティクス | 改変抗ＳＩＲＰａ抗体及びその使用 |
| EP3802602A1 (en) | 2018-05-25 | 2021-04-14 | Alector LLC | Anti-sirpa antibodies and methods of use thereof |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| KR20220091576A (ko) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| KR20260017503A (ko) | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| CN111635458B (zh) | 2020-03-20 | 2026-02-17 | 健信生物科技(宁波)有限公司 | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 |
| WO2022020583A1 (en) * | 2020-07-24 | 2022-01-27 | The Board Of Trustees Of The Leland Standford Junior University | Compositions and methods for modulation of sirpalpha-mediated signaling |
| CN112574310B (zh) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024527551A (ja) | 2021-06-29 | 2024-07-25 | シージェン インコーポレイテッド | 非フコシル化抗ｃｄ７０抗体及びｃｄ４７アンタゴニストの組み合わせを用いるがんを処置する方法 |
| CN113583979B (zh) * | 2021-08-03 | 2022-11-22 | 杭州荣谷生物科技有限公司 | 一种重组溶瘤痘苗病毒、制备方法及其用途 |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250282874A1 (en) | 2022-05-17 | 2025-09-11 | Suzhou Transcenta Therapeutics Co., Ltd. | Bifunctional protein, and preparation thereof and use thereof |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0914452A2 (en) | 1996-06-17 | 1999-05-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel ptp20, pcp-2, bdp1, clk and sirp proteins and related products and methods |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US8613922B2 (en) | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| US20100215640A1 (en) | 2003-04-24 | 2010-08-26 | The University Of North Carolina At Chapel Hill | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| ATE542830T1 (de) | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| US20100239578A1 (en) | 2007-10-11 | 2010-09-23 | University Health Network | Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| EP2630966B1 (en) | 2007-10-12 | 2017-04-19 | Massachusetts Institute of Technology | Vaccine nanotechnology |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| PL2995315T3 (pl) * | 2009-05-15 | 2024-04-22 | University Health Network | Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47 |
| GB201015765D0 (en) | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| EP3682896A1 (en) | 2011-04-28 | 2020-07-22 | University of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013056352A1 (en) | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| SI2804617T1 (sl) | 2012-01-17 | 2020-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Visokoafinitetni SIRP-alfa reagenti |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| AU2015229448B2 (en) | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| JP7078533B2 (ja) | 2015-10-21 | 2022-05-31 | オーエスイー イムノセラピューティクス | 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物 |
| SG11201808465UA (en) | 2016-04-14 | 2018-10-30 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| RS66062B1 (sr) | 2016-04-14 | 2024-11-29 | Ose Immunotherapeutics | Nova anti-sirpa antitela i njihove terapijske primene |
| JP7395471B2 (ja) | 2017-10-13 | 2023-12-11 | オーセ イミュノセラピューティクス | 改変抗ＳＩＲＰａ抗体及びその使用 |
-
2019
- 2019-03-13 AU AU2019233577A patent/AU2019233577A1/en not_active Abandoned
- 2019-03-13 JP JP2020546939A patent/JP2021517130A/ja active Pending
- 2019-03-13 CA CA3091468A patent/CA3091468A1/en active Pending
- 2019-03-13 US US16/979,627 patent/US11884723B2/en active Active
- 2019-03-13 CN CN201980031527.1A patent/CN112105646A/zh active Pending
- 2019-03-13 EP EP19711862.3A patent/EP3765512A1/en active Pending
- 2019-03-13 EA EA202091859A patent/EA202091859A1/ru unknown
- 2019-03-13 WO PCT/EP2019/056250 patent/WO2019175218A1/en not_active Ceased
- 2019-03-13 MX MX2020009121A patent/MX2020009121A/es unknown
- 2019-03-13 BR BR112020017709-1A patent/BR112020017709A2/pt not_active IP Right Cessation
- 2019-03-13 KR KR1020207029293A patent/KR20210006338A/ko not_active Ceased
-
2020
- 2020-09-07 CL CL2020002305A patent/CL2020002305A1/es unknown
- 2020-09-16 PH PH12020551491A patent/PH12020551491A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019175218A5 (https=) | ||
| Yaddanapudi et al. | Cancer vaccines: Looking to the future | |
| Schooten et al. | MAGE-A antigens as targets for cancer immunotherapy | |
| ES2328025T3 (es) | Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb. | |
| Kleinovink et al. | Combination of photodynamic therapy and specific immunotherapy efficiently eradicates established tumors | |
| Wei et al. | Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice | |
| Jemon et al. | An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy | |
| JP2021517130A (ja) | 抗ヒトＳＩＲＰａｖ１抗体の使用および抗ｖ１抗体を製造する方法 | |
| Lynam et al. | Immunotherapy for gynecologic cancer: current applications and future directions | |
| AU2012286690A1 (en) | Dendritic cell (DC)-vaccine therapy for pancreatic cancer | |
| JP2021512914A5 (https=) | ||
| Cao et al. | DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice | |
| WO2017084421A1 (zh) | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 | |
| Johnson et al. | Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule | |
| Rodriguez-Garcia et al. | T-cell target antigens across major gynecologic cancers | |
| Ma et al. | Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development | |
| JPWO2011129379A1 (ja) | 新規抗ｈｓｐ９０モノクローナル抗体 | |
| CN102170908A (zh) | 向个体的肿瘤引流淋巴结递送cd40激动剂 | |
| JP2025085695A (ja) | 既存の微生物免疫を利用した癌処置 | |
| Kumai et al. | Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor | |
| Hardwick et al. | New approaches for immune directed treatment for ovarian cancer | |
| Zhang et al. | Optimal combination treatment regimens of vaccine and radiotherapy augment tumor-bearing host immunity | |
| Carlring et al. | Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice | |
| Wang et al. | DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice | |
| CN115485031A (zh) | 方法和组合物 |